Gold Investment Management Ltd. Acquires 2,488 Shares of Pfizer Inc. (NYSE:PFE)

Gold Investment Management Ltd. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,801 shares of the biopharmaceutical company’s stock after buying an additional 2,488 shares during the period. Gold Investment Management Ltd.’s holdings in Pfizer were worth $1,338,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. QSM Asset Management Ltd grew its holdings in Pfizer by 51.7% during the first quarter. QSM Asset Management Ltd now owns 404,802 shares of the biopharmaceutical company’s stock valued at $10,118,000 after purchasing an additional 138,000 shares during the period. Money Concepts Capital Corp grew its holdings in Pfizer by 0.3% during the first quarter. Money Concepts Capital Corp now owns 208,604 shares of the biopharmaceutical company’s stock valued at $5,286,000 after purchasing an additional 533 shares during the period. Achmea Investment Management B.V. grew its holdings in Pfizer by 194.2% during the first quarter. Achmea Investment Management B.V. now owns 311,902 shares of the biopharmaceutical company’s stock valued at $7,904,000 after purchasing an additional 205,886 shares during the period. Philip James Wealth Mangement LLC grew its holdings in Pfizer by 3.4% during the first quarter. Philip James Wealth Mangement LLC now owns 331,466 shares of the biopharmaceutical company’s stock valued at $8,399,000 after purchasing an additional 11,035 shares during the period. Finally, Artemis Investment Management LLP grew its holdings in Pfizer by 30.4% during the first quarter. Artemis Investment Management LLP now owns 584,206 shares of the biopharmaceutical company’s stock valued at $14,804,000 after purchasing an additional 136,130 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $24.20 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a fifty day simple moving average of $23.46 and a 200 day simple moving average of $24.85. The stock has a market capitalization of $137.56 billion, a price-to-earnings ratio of 17.53, a PEG ratio of 0.88 and a beta of 0.57. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the firm posted $0.82 earnings per share. The company’s quarterly revenue was down 7.8% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.11%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PFE. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.